Pneumocystis pneumonia in patients treated with long-term steroid therapy for symptom palliation: a neglected infection in palliative care

Am J Hosp Palliat Care. 2014 Dec;31(8):857-61. doi: 10.1177/1049909113504238. Epub 2013 Sep 30.

Abstract

We report 3 cases of pneumocystis pneumonia (PCP) in patients with advanced cancer who received palliative care. All patients received long-term steroid therapy for symptom management. A diagnosis of PCP was based on clinical symptoms and a positive Pneumocystis jiroveci polymerase chain reaction test from induced sputum specimens. Despite appropriate treatment, only 1 patient recovered from PCP. Long-term steroid, often prescribed in palliative care settings, is the most common risk factor for PCP in non-HIV patients. Pneumocystis pneumonia may cause distressing symptoms such as severe dyspnea, and the mortality rate is high. Therefore, it is important to consider PCP prophylaxis for high-risk patients and to diagnose PCP early and provide appropriate treatment to alleviate PCP-related symptoms and avert unnecessary shortening of a patient's life expectancy.

Keywords: advanced cancer; palliative care; pneumocystis pneumonia; prophylaxis; steroid.

Publication types

  • Case Reports

MeSH terms

  • Betamethasone / adverse effects*
  • Betamethasone / therapeutic use
  • Dexamethasone / adverse effects*
  • Dexamethasone / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications
  • Neoplasms / drug therapy
  • Palliative Care / methods*
  • Palliative Care / statistics & numerical data
  • Pneumocystis carinii
  • Pneumonia, Pneumocystis / epidemiology
  • Pneumonia, Pneumocystis / etiology*
  • Risk Factors

Substances

  • Dexamethasone
  • Betamethasone